Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG001 ± lenvatinib in malignant mesothelioma
CTR20212699Phase 2Terminated
- Sponsor
- Shangjian Bio
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PBI-1308 in mesothelioma, sponsored by Shangjian Bio. Started Oct 2021; status: terminated.
02
Drugs
PBI-1308
03
Conditions
mesothelioma
Beyond the preview
Go deeper on CTR20212699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212699.